Tumor Lysis Syndrome: Causes and Management

Tumor Lysis Syndrome (TLS) is a potentially life-threatening condition that occurs when cancer cells break down rapidly. The sudden release of intracellular components into the bloodstream can lead to severe metabolic disturbances. Understanding the causes, symptoms, diagnosis, and management of TLS is crucial for healthcare professionals and patients alike.

What is Tumor Lysis Syndrome?

Tumor Lysis Syndrome usually occurs after the initiation of cancer treatment, especially chemotherapy. It most commonly affects patients with hematologic malignancies like leukemia and lymphoma. When cancer cells die off quickly, they release large amounts of potassium, phosphate, and nucleic acids into the blood. These substances can overwhelm the body's normal metabolic processes.

Get a second opinion from trusted experts and makeconfident, informed decisions.

Get Second Opinion

Causes of Tumor Lysis Syndrome

The primary cause of TLS is the rapid destruction of malignant cells. While this is a desired outcome of cancer treatment, it can lead to complications if not managed properly. Factors that increase the risk of TLS include:

High tumor burden
High sensitivity of cancer cells to treatment
Pre-existing kidney dysfunction
Dehydration

Certain cancers, like Burkitt lymphoma and acute lymphoblastic leukemia, are more likely to cause TLS due to their rapid growth and high cell turnover.

Symptoms of Tumor Lysis Syndrome

The symptoms of TLS can be quite varied and may appear within hours to days after starting cancer treatment. Key symptoms include:

Nausea and vomiting
Diarrhea
Muscle cramps or spasms
Fatigue
Irregular heartbeats
Seizures

These symptoms result from the metabolic imbalances caused by the release of intracellular contents into the bloodstream.

Metabolic Disturbances in TLS

The primary metabolic disturbances seen in TLS are:

Hyperkalemia: Elevated potassium levels can cause cardiac arrhythmias and muscle weakness.
Hyperphosphatemia: Increased phosphate levels can lead to secondary hypocalcemia, causing muscle cramps and tetany.
Hyperuricemia: Elevated uric acid levels can result in gout and acute kidney injury.
Hypocalcemia: Low calcium levels can cause neuromuscular irritability and seizures.

Your health is everything - prioritize your well-being today.

Schedule Your Appointment

Diagnosing Tumor Lysis Syndrome

Diagnosing TLS involves a combination of clinical evaluation and laboratory tests. Key diagnostic criteria include:

Elevated serum potassium, phosphate, and uric acid levels
Decreased serum calcium levels
Signs and symptoms consistent with TLS

Healthcare providers often use the Cairo-Bishop criteria, which classifies TLS into laboratory TLS (based on lab values) and clinical TLS (based on lab values plus clinical symptoms).

Laboratory Tests for TLS

Common laboratory tests used in diagnosing TLS include:

Blood tests for electrolytes (potassium, calcium, phosphate)
Uric acid levels
Kidney function tests (creatinine, blood urea nitrogen)
Complete blood count (CBC)

These tests help in early identification and management of metabolic disturbances associated with TLS.

Managing Tumor Lysis Syndrome

Early recognition and prompt management of TLS are essential to prevent severe complications. Management strategies typically involve a combination of preventive measures and active treatments.

Preventive Measures

Hydration: Adequate hydration helps dilute the concentration of released intracellular contents and promotes their excretion through urine. Intravenous (IV) fluids are often administered to maintain high urine output.
Medications: Allopurinol or rasburicase may be given to reduce uric acid levels. Allopurinol prevents the formation of uric acid, while rasburicase breaks down existing uric acid.
Monitoring: Frequent monitoring of electrolytes and kidney function helps in early detection of metabolic imbalances.

Active Treatment

If TLS develops despite preventive measures, active treatment may be necessary:

Electrolyte Management: Hyperkalemia, hyperphosphatemia, and hypocalcemia are managed using medications and, in severe cases, dialysis.
Dialysis: Hemodialysis or continuous renal replacement therapy (CRRT) may be required for patients with acute kidney injury or severe electrolyte imbalances.
Supportive Care: Symptomatic treatment for nausea, vomiting, and seizures is provided as needed.

Find Our Specialists

Book Doctor Appointment